Detailed Coverage

Solara Active Pharma Sciences Posts Profit Growth in Q1 FY27

Consolidated Net Profit (June 30, 2026): ₹16.31 crore
Consolidated Revenue (June 30, 2026): ₹381.60 crore

Reader Takeaway: Profitability improves year-on-year, but significant accumulated losses and reliance on working capital remain key concerns.

What just happened

Solara Active Pharma Sciences reported a consolidated net profit of ₹16.31 crore for the quarter ended June 30, 2026. This represents an increase from ₹9.60 crore in the previous quarter (ended March 31, 2026) and ₹10.52 crore in the same quarter last year (ended June 30, 2025). Revenue from operations for the quarter stood at ₹381.60 crore.

The company also provided an update on its corporate actions. As of June 30, 2026, Solara Active Pharma Sciences had raised ₹442.73 crore out of its ₹449.95 crore rights issue. Furthermore, it has incorporated 'Synthix Global Pharma Solutions Limited' on April 29, 2025, as part of its plan to demerge its CRAMS and Polymers business.

Why this matters

The profit improvement is a positive sign for shareholders, indicating a potential turnaround in operational performance. The progress on the rights issue and the strategic demerger could unlock value and streamline the business. However, the company continues to grapple with significant accumulated losses.

The backstory

Solara Active Pharma Sciences has been undergoing a period of restructuring and operational challenges. The rights issue aims to strengthen its financial position, while the demerger is intended to create focused entities. The company's financial health has been a key area of focus for investors, given its past performance.

What changes now

The improved profitability and progress on strategic initiatives like the demerger could set the stage for a more stable financial future. The company's ability to successfully manage its accumulated losses and maintain access to working capital will be crucial going forward.

Risks to watch

• Accumulated Losses: The ₹286.21 crore in accumulated losses presents a significant risk. Continuous operational improvements are needed to offset this.
• Liquidity: The going concern status depends on renewing working capital facilities and achieving revenue/margin growth targets.

Auditor and Compliance

The statutory auditors have provided an unmodified conclusion on both standalone and consolidated financial results for the quarter ended June 30, 2026, confirming the accuracy of the reported figures.

Investor Takeaway

Solara Active Pharma Sciences shows improving profitability but faces challenges with accumulated losses. Investors should monitor the demerger execution and the company's ability to secure working capital and grow revenues.